New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rabies vaccine 2.5 [iu] - injection with diluent - 2.5 iu - active: rabies vaccine 2.5 [iu] excipient: disodium edetate potassium l-glutamate polygeline sodium chloride sucrose trometamol water for injection - active immunisation against rabies virus, including (a) pre-exposure immunisation, (b) post-exposure treatment following exposure to rabies virus

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - monobasic sodium phosphate, quantity: 1.936 g - tablet, effervescent - excipient ingredients: potassium bicarbonate; citric acid; sucrose; macrogol 4000; saccharin sodium; sodium bicarbonate; flavour - 1) hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis, and metastatic bone disease.,2) hypophosphataemia associated with vitamin d resistant rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 1 mg/ml - injection - excipient ingredients: sodium chloride; water for injections - benzatropine injection is recommended for all forms of parkinsonism - including arteriosclerotic, post-encephalitic, idiopathic, as well as drug induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful antichlolinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-drug-induced parkinsonism, partial control of symptoms is usually achieved.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate, quantity: 5.7 mg - injection - excipient ingredients: sodium chloride; sodium metabisulfite; water for injections; sodium hydroxide; tartaric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - metaraminol tartrate, quantity: 9.5 mg - injection - excipient ingredients: sodium chloride; water for injections; sodium metabisulfite; sodium hydroxide; tartaric acid - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.,it may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - methylene blue, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - methylene blue injection usp is indicated: for the treatment of drug-induced methaemoglobinaemia; for the treatment of idiopathic methaemoglobinaemia (in which structural abnormality of haemoglobin is not present); as a bacteriological strain as a dye in diagnostic procedures such as fistula detection; for the delineation of certain body tissues during surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - digoxin-specific antibody fragment f(ab) (ovine), quantity: 40 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate - digoxin-specific antibody fragment f(ab) (ovine) digifab is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. consequences of multiple dosing with digifab have not been evaluated.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - colistimethate sodium, quantity: 1 million iu - inhalation - excipient ingredients: - tadim powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible pseudomonas aeruginosa in patients with cystic fibrosis. consideration should be given to official guidance on the appropriate use of antibacterial agents.